Lassa virus (LASV) is endemic in the rodent populations of Sierra Leone, Nigeria and other
countries in West Africa. Spillover to humans occurs frequently and results in Lassa fever, a …

Antibodies have been used for more than 100 years in the therapy of infectious diseases,
but a new generation of highly potent and/or broadly cross-reactive human monoclonal …

The Lassa virus is endemic in parts of West Africa, and it causes hemorrhagic fever with high
mortality. The development of a recombinant protein vaccine has been hampered by the …

Background Lassa fever is a viral haemorrhagic disease endemic to west Africa. No large-
scale studies exist from Nigeria, where the Lassa virus (LASV) is most diverse. LASV …

Lassa virus (LASV) is recognized by the World Health Organization as one of the top five
pathogens likely to cause a severe outbreak. A recent unprecedented resurgence of LASV …

Developing potent therapeutics and effective vaccines are the ultimate goals in controlling
infectious diseases. Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects …

Lassa fever, is an acute zoonotic disease of humans that is mainly endemic to West African
countries of Guinea, Liberia, Nigeria, and Sierra Leone. 1–3 Other countries such as Mali …

Crimean-Congo hemorrhagic fever virus (CCHFV) is a World Health Organization priority
pathogen. CCHFV infections cause a highly lethal hemorrhagic fever for which specific …

Lassa fever (LF), caused by Lassa virus (LASV), is a viral hemorrhagic fever for which no
approved vaccine or potent antiviral treatment is available. LF is a WHO priority disease and …

There are no approved treatments for Lassa fever (LF), which is responsible for thousands of
deaths each year in West Africa. A major challenge in developing effective medical …